How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?
- Resource Type
- Authors
- Joseph Tibaldi; Jodi Strong; Max E. Mercado
- Source
- Clinical Diabetes : A Publication of the American Diabetes Association
- Subject
- Insulin degludec
medicine.medical_specialty
Post hoc
business.industry
Liraglutide
Endocrinology, Diabetes and Metabolism
030209 endocrinology & metabolism
Hypoglycemia
medicine.disease
Feature Articles
Clinical trial
Clinical Practice
03 medical and health sciences
0302 clinical medicine
Internal Medicine
Medicine
030212 general & internal medicine
business
Fixed ratio
Intensive care medicine
Glycemic
medicine.drug
- Language
- ISSN
- 1945-4953
0891-8929
The efficacy and safety of the fixed-ratio combination of insulin degludec (degludec) and liraglutide (IDegLira) were confirmed in the DUAL clinical trial program, in which IDegLira demonstrated superior or noninferior glycemic control over comparators in addition to its low risks of hypoglycemia and weight gain. This article identifies the patient types for whom IDegLira is most appropriate by reviewing the DUAL results and subsequent post hoc analyses and presenting real-world cases in which IDegLira has been used effectively in U.S. clinical practice. In the clinic, IDegLira has been used effectively when patients wanted to avoid more complex injectable regimens, particularly those with renal insufficiency for whom treatment options are limited.